We are City of Hope. We combine science with soul to create miracles. 2015 Annual Report.
Contents

02 Leadership Message
Robert W. Stone shares how City of Hope accelerated its mission in 2015

04 Points of Distinction
City of Hope sets itself apart in many ways

06 The Science Behind Hope
Researchers are racing to save lives — and winning

10 Survivor Stories
Now cancer-free, three survivors share their City of Hope stories

12 Our Latest Breakthroughs
Highlights of our most exciting innovations in 2015

15 On the Horizon
Behnam Badie, M.D., and Christine Brown, Ph.D., are developing breakthrough treatments for patients with brain tumors

16 New to City of Hope
Meet the newest members of our world-class team

18 In the News
Everyday miracles make headlines and a difference in people’s lives

20 Events
Some of our proudest moments in 2015

22 Partners in Hope
Donors who are making a demonstrable difference in our future

24 Spirit of Life® Award
Celebrating philanthropists’ impact on our mission and our patients

25 Board of Directors
At the helm of advancing scientific research and our lifesaving work

27 Selected Financials
FY2015 information about City of Hope and affiliates
On the cover Gus Perez, chronic myelogenous leukemia survivor: “City of Hope is more than just medical treatment,” says the Los Angeles firefighter. “They put you back together from the ground up.” See Gus’s story on page 10.

We push the boundaries of science and medicine to outsmart cancer. At City of Hope, our groundbreaking scientific research works hand-in-hand with compassionate care to produce medical miracles, making lives whole again.
City of Hope is an independent, biomedical research institution and comprehensive cancer center committed to researching, treating and preventing cancer, with an equal commitment to curing and preventing diabetes and other life-threatening diseases.
City of Hope has always been at the forefront of bench-to-bedside treatments and unparalleled compassionate care. In 2015, we accelerated our mission — reaching more people, healing more patients and pushing the envelope on science and research like never before.

In this annual report, you will get a snapshot of some of our patient success stories and the lifesaving innovations that made it all possible. Take a moment to read about some of the people who helped make it happen. People like our gene therapy pioneer John Zaia, M.D., whose work aims at bringing about a functional HIV cure. Gifted researchers like Hua Yu, Ph.D., Andreas Herrmann, Ph.D., Don Diamond, Ph.D., and Vincent Chung, M.D., who are developing new strategies to enable our immune systems to destroy cancer.

We are achieving promising results across the board: gene therapy, targeted therapy, immunotherapy and all aspects of precision medicine. We are growing beyond our Duarte campus, expanding community practice centers across Southern California and forging new partnerships and collaboration agreements around the world.

Together, we are advancing this work thanks to the enduring commitment and generosity of our donors, volunteers and supporters. Our ability to have an impact on humanity is greater now than it has ever been before.

I hope you feel the pride in our work and that you share my excitement and optimism about our future.

Robert W. Stone
President and Chief Executive Officer
Points of Distinction

- Treated 6,836 new patients at our main campus in Duarte and 16,233 at our community practice sites
- We have performed more than 12,000 bone marrow and stem cell transplants, with survival rates that are unparalleled
- Total value of community benefit investments $96,392,050
- Awarded more than $72.9 million in research grants in the 2015 fiscal year
- Ranked among the nation’s Best Cancer Hospitals by U.S. News & World Report for more than 10 years
- More than 300 patents and almost 30 drugs in the pipeline at any given time
- Each year, City of Hope conducts more than 300 clinical trials enrolling more than 5,000 patients
- Total value of community benefit investments
  - Medical Care Service Benefits $26,257,095
  - Health Research Education Training $66,743,167
  - Benefits for Broader Community $3,391,788
With a proven leadership in cancer, diabetes and HIV/AIDS, we are targeting some of the most devastating diseases facing humankind.

Institutional Distinctions

• City of Hope has a flexibility that larger institutions typically lack. Innovative concepts move quickly from the laboratory to patient trials — and then to market, where they benefit patients around the world.

• Three on-campus manufacturing facilities produce both biologic and chemical compounds to good manufacturing practice (GMP) standards. This infrastructure helps us quickly turn breakthrough discoveries into lifesaving therapies.

• As a founding member of the National Comprehensive Cancer Network, our research and treatment protocols advance care throughout the nation.

• We are part of ORIEN (Oncology Research Information Exchange Network), the world’s largest cancer research collaboration devoted to precision medicine.

• We continue to receive the highest level of accreditation by the American College of Surgeons Commission on Cancer for our exceptional level of cancer care, “Three-Year with Commendation.”

A Record of Innovation

• City of Hope is a pioneer in bone marrow and stem cell transplants. Our program is now one of the largest and most successful of its kind in the world.

• Numerous breakthrough cancer drugs, including Herceptin, Rituxan, Erbitux, and Avastin, are based on technology pioneered by City of Hope and are saving lives worldwide.

• To date, our surgeons have performed more than 10,000 robotic procedures for prostate, kidney, colon, liver, bladder, gynecologic, oral and other cancers.

• We are a national leader in islet cell transplantation, which has the potential to reverse type 1 diabetes. We also provide islet cells for research at other institutions throughout the U.S.

• Millions of people with diabetes benefit from synthetic human insulin, developed through research conducted at City of Hope.

• Our scientists are pioneering the application of blood stem cell transplants to treat patients with HIV- and AIDS-related lymphoma. Using a new form of gene therapy, our researchers achieved the first long-term persistence of anti-HIV genes in patients with AIDS-related lymphoma — a treatment that may ultimately cure lymphoma and HIV/AIDS.
The Science Behind Hope

We’re in the race to save lives. And we intend to win.
Kimlin Tam Ashing, Ph.D., professor and director of the Center of Community Alliance for Research & Education at City of Hope, is leading efforts to improve health and well-being, especially in communities most vulnerable to poor health due to poverty, violence or lack of social supports. City of Hope has been selected to join the national program, SCALE (Spreading Community Accelerators through Learning and Evaluation), to help communities improve the health of targeted populations.

Don J. Diamond, Ph.D., Vincent Chung, M.D., and other City of Hope researchers launched a clinical trial seeking ways to effectively activate a patient’s own immune system to fight his or her cancer. The team is combining an immune-boosting vaccine with a drug that inhibits tumor cells’ ability to grow — to encourage immune cells to attack and eliminate tumors such as nonsmall cell lung cancer, melanoma, triple-negative breast cancer, renal cell carcinoma and many other cancer types.

Fouad Kandeel, M.D., Ph.D., is leading an islet cell transplantation clinical trial that may be the first step in a wider effort to permanently cure type 1 diabetes. Physicians in the newly launched Diabetes & Metabolism Research Institute at City of Hope are providing the still-experimental procedure to suitable candidates in hopes of supplying the patients with insulin-producing cells of their own.

“We are one of only a few islet cell transplant programs in the country,” says Kandeel. “This trial, in addition to providing a much needed potential cure for patients with severe type 1 diabetes, will also be vital in opening the door to other major studies to address the medical needs of these patients.”
“We could see a functional cure for HIV in the next five to 10 years.”
— John A Zaia, M.D.
John A. Zaia, M.D., is working to maximize the potential of gene therapy for HIV, cancer and other diseases. The gene therapy pioneer serves as director of the Center for Gene Therapy within City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute, as well as principal director of our new Alpha Clinic. In these dual roles, Zaia is helping to identify new stem cell therapies for currently incurable diseases, bridging the gap between the promise and the reality of stem cell treatments.

Christine Pechera, non-Hodgkin lymphoma survivor
Told she had only months to live in 2006 after chemotherapy failed, Christine Pechera turned to City of Hope and received a bone marrow transplant. Cancer-free today, the writer and filmmaker declares, “City of Hope offers options that other hospitals don’t. This is the place that saved my life.”
I Am a Miracle.
City of Hope’s research innovations are saving lives around the world. Here, three survivors share their “miraculous” stories of science with soul.

“Gus Perez” “City of Hope literally gave me my life back.”

Eleven years ago, Los Angeles firefighter Gus Perez was facing a battle far greater than any he’d ever known. He was diagnosed with CML, chronic myelogenous leukemia.

Gus began receiving the drug Gleevec, which put him into remission. Given the drug’s success, he almost resigned himself to staying on it, yet was drawn to another option: undergoing a bone marrow transplant at City of Hope.

“I went to my favorite ocean spot,” Gus recalls. “I put on my wetsuit, like I’ve done thousands of times, and paddled out. Every wave was special because I wasn’t sure if I was ever going to be back. And I remember getting out of the water and counting the steps to my car, thinking, ‘I’m going to beat this. I’m going to retrace those steps.’ And I’m happy to say I was able to do it.”

Gus and his family recently celebrated the 10th anniversary of his bone marrow transplant.

“City of Hope is more than just medical treatment,” Gus says. “They have to put you back together from the ground up. And to me, that’s truly a miracle.”
Nicole Schulz “I’m back now and making up for lost time.”

“Never give up. That’s what I tell kids at City of Hope today. It’s the unofficial motto around here.”

As an active 14-year-old, Nicole Schulz loved cheerleading and hanging out with her friends. Then her whole world changed. Nicole learned that her fatigue and other symptoms weren’t “just the flu,” but the effects of acute myelogenous leukemia, an aggressive disease that rendered her bone marrow 97 percent cancerous.

Nicole spent the next three and a half months at City of Hope, fighting the cancer with a daily regimen of chemotherapy and blood and platelet transfusions.

“It put me into remission,” Nicole says. “But I wasn’t cured. And I wanted a cure.”

Fortunately, Nicole was a candidate for a bone marrow transplant. Her malfunctioning marrow cells would be replaced with healthy marrow from a matching unrelated donor.

“I never gave up — and neither did City of Hope,” Nicole says. After two bone marrow transplants and tremendous perseverance, Nicole is back to living the life she once knew and quickly making up for lost time.

Jim Murphy “This is what City of Hope does. They do cancer.”

“When Jim Murphy’s doctor called and asked to see him on Christmas Eve, Jim knew it wasn’t going to be good news. And he was right.

“The diagnosis was esophageal cancer,” Jim says. “Once they tell you that, there’s nothing you can do but formulate your action plan.” Jim would need to undergo chemotherapy, radiation and surgery to remove the tumor from his esophagus. It would require taking two-thirds of his esophagus and a third of his stomach.

Despite the intense treatment, Jim was determined to keep his life as normal as possible. Throughout his chemotherapy and radiation therapy, he never missed a day of work, even riding his mountain bike to and from City of Hope to take his treatments.

“I needed to show myself one victory after another,” Jim says. “I know City of Hope appreciated the fact that I was fighting as hard as they were.”

Now cancer-free for several years, Jim credits City of Hope with giving him the best chance to fight his disease. “What really impressed me was that the research was right there at City of Hope. If they have something experimental, it goes from the researcher, right to the doctor and right to you. It’s the ultimate weapon — doctors reaching out for researchers, researchers reaching out for doctors. And the patient wins.”

“Cancer is not a death sentence. It’s a disease. And I was determined to treat it as such.”
Our Latest Breakthroughs
We’re coming at cancer in ways cancer doesn’t see coming.

City of Hope is dedicated to lifesaving innovations. Here are a few highlights of the breakthrough science underway.

A City of Hope brain tumor patient was the first to be treated by City of Hope’s Alpha Clinic, one of several clinics created to speed the development and delivery of stem cell therapies to patients who desperately need them. The patient underwent surgery for recurring glioblastoma and participated in a clinical trial using genetically modified neural stem cells to help deliver chemotherapy that targets brain cancer cells.

City of Hope researchers identified a promising new strategy for dealing with PDAC, an aggressive form of pancreatic cancer. The bacterial-based therapy homes to tumors and provokes an extremely effective tumor-killing response. In a preclinical study published in Cancer Immunology Research, the team reported that the therapy frequently triggered the complete regression of pancreatic tumors and significantly extended survival in mice. The researchers believe the new therapy may have applications far beyond pancreatic cancers and hope to bring it into clinical trials soon.

Teams at City of Hope are working to load nanoparticles with small snippets of DNA molecules that can stimulate the immune system to attack tumor cells in the brain. This innovative approach can overcome the blood-brain barrier, which blocks many drugs from reaching the tumor site.

A pioneer in islet cell transplantation for the treatment of diabetes, City of Hope conducted a clinical trial to refine its transplantation protocol. Because this new protocol includes an ATG (antithymoglobulin) induction, the immune system will not harm the transplant. The immune-suppression strategy used in the trial is considered a significant improvement over the protocol used in previous islet cell transplant trials.
City of Hope physicians and scientists joined a multinational team in reporting the success of a phase II clinical trial of a novel drug against essential thrombocythemia (ET). ET patients make too many platelets (cells essential for blood clotting), which puts them at risk for abnormal clotting and bleeding. All 18 patients treated with the drug imetelstat exhibited decreased platelet levels, and 16 showed normalized blood cell counts. The trial was published in the *New England Journal of Medicine*. Eight of the patients were treated at City of Hope.

City of Hope researchers have developed two approaches using stem cells that may someday cure HIV/AIDS. One aims to spur the immune system to produce T cells resistant to HIV by infusing a patient with altered stem cells. Another uses an enzyme that can edit stem cell genes so they no longer produce a key protein that the virus requires to infect cells.

Researchers found that the CMV PepVax vaccine — developed at City of Hope to boost cellular immunity against cytomegalovirus (CMV) — is safe and effective in stem cell transplant recipients. Building on this discovery, City of Hope and Fortress Biotech formed a company to develop two vaccines, PepVax and Triplex, against CMV, a life threatening illness in people who have weakened or underdeveloped immune systems such as cancer patients and developing fetuses. The vaccines are the subjects of multisite clinical trials. These City of Hope vaccines could open the door to a new way of protecting cancer patients from CMV, a devastating infection that affects hundreds of thousands of people worldwide.
FOR PATIENTS WITH
ADVANCED BRAIN CANCER,
A PROMISING MIRACLE OF SCIENCE

The research being done with CAR-T cells is groundbreaking. It will change the way we approach brain tumors.

Finding effective ways to destroy brain tumors has eluded researchers for decades. Here, Behnam Badie, M.D., chief of the Division of Neurosurgery, and Christine Brown, Ph.D., the Heritage Provider Network Professor in Immunotherapy and associate director of the T Cell Therapeutics Research Laboratory, discuss new breakthroughs in conquering brain cancer at City of Hope.
Brown High-grade brain tumors such as glioblastoma are one of the least curable of all cancers. This challenge is a driving force behind our development of new treatments such as CAR–T cell immunotherapy.

Badie One problem is cancer’s ability to hide from the patient’s immune system. In June 2015, we began the first in-human clinical trials of a unique approach to deploy a patient’s own modified T cells to target cancer at the tumor site.

Brown With CAR–T cell therapy, we collect a patient’s own T cells and then genetically modify them to produce chimeric antigen receptors (CARs). Once injected back into the patient, these CAR–T cells recognize cancer cells — and kill them.

Badie In our trial, patients with advanced brain tumors received injections of modified CAR–T cells directly at the tumor site. We are the only center actually doing it this way — and it is working.

Brown Our early clinical results have been very promising. So far, for the patients we have treated, this therapy has been very safe and our ultimate goal is to improve outcomes for patients battling this devastating disease.

Badie For patients in this clinical trial, there has been almost no toxicity. They haven’t experienced any nausea or vomiting, and they’ve had very minor headaches and very low-grade fevers. Plus, it’s an outpatient treatment.

Badie Besides CAR–T research, we also look forward to testing the new stem cells to help deliver chemotherapy to patients with brain tumors. Initial trials have also been very promising, and a new design of the stem cells is being used in a new clinical trial.

This could take the treatment of brain tumors to the next level and open up a new avenue of treatment to patients who badly need it.

Brown The data from our preclinical studies gave us confidence that this treatment has the potential to be very powerful and last longer than previous attempts at immunotherapy for brain cancer.

Of course, several centers offer CAR–T cell therapy in human clinical studies. But City of Hope is the only institution administering the CAR–T cells directly at the brain tumor site.

Brown The data from our preclinical studies gave us confidence that this treatment has the potential to be very powerful and last longer than previous attempts at immunotherapy for brain cancer.

Of course, several centers offer CAR–T cell therapy in human clinical studies. But City of Hope is the only institution administering the CAR–T cells directly at the brain tumor site.

At City of Hope, these milestones are the result of research and clinical expertise working in unison. It’s exciting to see our CAR–T cell research translated to a clinical trial. This collaboration of basic science and clinical expertise provides a unique benefit for our patients.
Kristin Bertell joins City of Hope to provide executive and strategic oversight for all aspects of City of Hope’s philanthropic efforts as we enter a new era of growth and development.

Recently named Outstanding Fundraising Professional of the Year by the San Diego chapter of the Association of Fundraising Professionals, Bertell served as associate vice chancellor of health sciences development at UC San Diego. She led a team that raised $320 million in private philanthropic support — the largest fundraising goal ever met for UC San Diego Health Sciences. She also was primary development lead in securing a landmark donation that helped establish the Sanford Stem Cell Clinical Center.

At City of Hope, Bertell leads a strategic vision and sustainable growth plan for our organization’s philanthropic efforts. She works closely with executive team members, research and physician leaders, and the individuals, corporations and foundations that support City of Hope’s work.

Larry W. Kwak, M.D., Ph.D., is a world-renowned physician and scientist who has pioneered breakthrough innovations in immunology and cancer vaccines. He joins City of Hope after a decade of leadership in lymphoma and myeloma research and treatment at MD Anderson Cancer Center in Houston.

Named one of TIME magazine’s 100 Most Influential People in 2010, Kwak is the associate director for translational research and developmental therapeutics, director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute and is endowed with the title of Dr. Michael Friedman Professor in Translational Medicine.

Passionate about harnessing the body’s immune system to battle cancer, Kwak takes special pride in his ability to rapidly translate basic research into human clinical trials.
Christiane Querfeld, M.D., Ph.D., joins City of Hope as a dermatologist and dermatopathologist specializing in the diagnosis and treatment of cutaneous lymphoma, a rare form of lymphoma which first appears on the skin but can spread to lymph nodes and internal organs.

Querfeld received her medical degree at the University of Cologne and a Ph.D. at the University of Heidelberg. She completed training at Johns Hopkins University, University of Chicago and Northwestern University, specializing in dermatopathology and cutaneous lymphoma diagnosis and treatment. In 2014, following her work at Memorial Sloan Kettering Cancer Center in New York, she joined City of Hope — one of the few institutions in the U.S. that currently offers clinical trials to help treat patients with cutaneous lymphomas.

A recognized authority in the field, Querfeld has published some 80 scholarly articles on cutaneous lymphoma.

Guido Marcucci, M.D., plays a key role in further expanding and broadening City of Hope’s world-renowned work in leukemia research and treatment. He is the co-director of our new Gehr Family Center for Leukemia Research and serves as chief of the Division of Hematopoietic Stem Cell and Leukemia Research.

Marcucci joins City of Hope from The Ohio State University, where he was a professor of internal medicine, molecular virology, immunology, medical genetics and pharmaceutics in the Division of Hematology at the university’s comprehensive cancer center.

A nationally recognized authority on leukemia, Marcucci has lectured around the world and authored more than 270 scholarly papers on the subject. He has received numerous competitive National Cancer Institute grants for his clinical and research work focused on the pathogenesis, treatment and prognostic assessment of patients with acute myeloid leukemia. He serves on the editorial board of three journals, including Blood and the Journal of Clinical Oncology.

“I have always been interested in answering the fundamental questions of what events initiate cancer, and I believe that leukemia can be used as a model to answer these questions.”

— Guido Marcucci, M.D., Co-director, Gehr Family Center for Leukemia Research

“I care deeply about my patients. They really are a part of my family. At the end of the day, it is always about helping patients get better so they can go on to continue living normal lives.”

— Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, Toni Stephenson Lymphoma Center

Christiane Querfeld, M.D., Ph.D., joins City of Hope as a dermatologist and dermatopathologist specializing in the diagnosis and treatment of cutaneous lymphoma, a rare form of lymphoma which first appears on the skin but can spread to lymph nodes and internal organs.

Querfeld received her medical degree at the University of Cologne and a Ph.D. at the University of Heidelberg. She completed training at Johns Hopkins University, University of Chicago and Northwestern University, specializing in dermatopathology and cutaneous lymphoma diagnosis and treatment. In 2014, following her work at Memorial Sloan Kettering Cancer Center in New York, she joined City of Hope — one of the few institutions in the U.S. that currently offers clinical trials to help treat patients with cutaneous lymphomas.

A recognized authority in the field, Querfeld has published some 80 scholarly articles on cutaneous lymphoma.
City of Hope launched its new Alpha Clinic, thanks to an $8 million, five-year grant from the California Institute for Regenerative Medicine (CIRM). The award is part of CIRM’s Alpha Stem Cell Clinics program, which aims to create one-stop centers for clinical trials focused on stem cell treatments for currently incurable diseases. Initial clinical trials may involve transplants of blood stem cells modified to treat patients with AIDS and lymphoma, neural stem cells to deliver drugs directly to cancers hiding in the brain, and T cell immunotherapy trials.

An agreement between City of Hope and Caltech will expand access to resources, facilities, educational opportunities and greater collaboration between some of the most innovative thinkers in technology, medicine and science. The agreement is expected to result in pathways to new and better medical treatments for some of the most serious health threats.

For the seventh year in a row, City of Hope received national recognition for its top-quality patient care from Press Ganey, an independent arbiter of patient satisfaction. Both the Press Ganey Guardian of Excellence Award and the Pinnacle of Excellence Award are based on patient feedback surveys.

City of Hope announced seven winners of its first-ever Healthy Living grants to help San Gabriel Valley residents reduce their risk of cancer and diabetes by making healthy lifestyle choices. The groups were selected to receive the $5,000 grants based on their programs’ creativity, sustainability, impact and accountability.

The National Institutes of Health awarded City of Hope a five-year, $4.8 million grant to study the possible role of chemicals in the environment in the development of breast cancer during the menopausal transition in women.

Renowned health care leader Glenn D. Steele Jr., M.D., Ph.D., agreed to join the City of Hope board of directors beginning January 2016. He recently served as president and chief executive officer of Geisinger Health System.
City of Hope launched its first-ever national advertising campaign, “The Miracle of Science with Soul.” Showcasing innovations in research and treatment, the popular campaign raises awareness of City of Hope’s unique approach and the scientific breakthroughs that help patients around the world. Bold graphics and the stories of survivors bring City of Hope dramatically to life via print, TV and outdoor advertising, as well as new site design and must-see videos at CityofHope.org.

The campaign raises City of Hope’s profile nationwide, building a strong presence that tells the full story of our institution and helps millions of people to understand the impact of our research innovations that save lives around the world. Appearing in leading publications such as O Magazine, The New York Times Magazine and Trib Magazine from the Chicago Tribune, it expands awareness among patients, physicians, nurses, donors, current and future employees, the medical community and the media. It gives City of Hope “credit” for our scientific innovations. And it enhances our ability to grow clinically, scientifically and philanthropically.
**Events**

**City of Hope’s 18th Annual Walk for Hope**
On Nov. 2, 2014, nearly 8,000 participants gathered at City of Hope for the 18th annual Walk for Hope — the only walk series that benefits research, treatment and education programs for all cancers unique to women. Every cent raised supports City of Hope’s Women’s Cancers Program. And with more than 600 survivors in attendance, the impact of City of Hope’s miracle of science with soul is clear. Walk for Hope events also took place in Phoenix, Seattle and Philadelphia, as well as the Hike for Hope in Palm Springs, California.

**Rose Parade**
On New Year’s Day, six City of Hope survivors and their families greeted 2015 by waving from City of Hope’s Tournament of Roses Parade float. Its theme “Made Possible By HOPE” said it all.

**Northern Trust Open**
On Feb. 19, 2015, one of the most respected tournaments of the PGA TOUR teed off at the Riviera Country Club in L.A., raising funds and awareness for City of Hope (the official charity of the Northern Trust Open). Each birdie scored during the event raised a total of over $750,000 for City of Hope as part of the 2015 Birdies for Hope program.

**Yoga for Hope**
In 2015, yoga practitioners in San Francisco, San Diego and Seattle put down their mats to raise funds for City of Hope research and treatment. Now in its fifth year, Yoga for Hope embodies our mission of sustaining the mind and body while supporting the search for cures for life-threatening illnesses.
City of Hope’s 39th Annual Bone Marrow Transplant Reunion
Thousands of people attended City of Hope’s 39th Annual Bone Marrow Transplant Reunion at City of Hope in May 2015. During this dream-come-true event in Duarte, California, survivors met their “superheroes” — the donors who provided stem cells to save the lives of strangers.

City of Hope Community Science Festival
City of Hope researchers offered science and healthy living activities at the second Community Science Festival in May 2015. Geared to middle school-aged kids and their families, this free event features hands-on activities, prevention and wellness tips, and demonstrations by City of Hope scientists.

City of Hope Celebrity Softball Game
In a play to strike out cancer, more than 25 music and sports stars stepped up to the plate at City of Hope’s 25th annual Celebrity Softball Game in June 2015. The game takes place during the CMA Music Festival in Nashville, Tennessee, at Hershel Greer Stadium. Joining this year’s lineup was survivor Stephen Bess, who received lifesaving treatment for acute lymphoblastic leukemia at City of Hope. Before taking the field, Bess met his “superhero” stem cell donor for the first time in a special ceremony.

Diversity Health Care Career Expo
In September 2015, City of Hope hosted the second Diversity Health Care Career Expo, to create awareness among students and professionals of the many opportunities available in the health care field.
Norman Payson, M.D., and Melinda Payson understand that giving now ensures a strong future. Establishing several prestigious endowed professorships in medicine this year, their philanthropy to City of Hope shows that commitment — and is an extraordinary investment in people’s health, today and for years to come.

The Leo and Anne Albert Charitable Trust, administered by Gene M. Pranzo, Trustee, supports pancreatic cancer research at City of Hope. The Albert Trust has supported several significant research initiatives, provided seed grants to young investigators and funded a pancreatic cancer research symposium at City of Hope with researchers from all over the United States.

With a goal to accelerate advances in treatment through increased collaboration, Michael Brinkenhoff, M.D., and his company, RevitaLash Cosmetics, made a generous gift to fund the Gayle Brinkenhoff Breast Cancer Symposium in memory of his late wife. The gift will support the symposium for five years.

At City of Hope, we focus our resources where we know they'll make the most impact. Our donors make a demonstrable difference in our future.
Beckman Research Institute of City of Hope was awarded a three-year, $778,521 grant from the Cambia Health Foundation. The grant will support the development of an online ELNEC (End-of-Life Nursing Education Consortium) curriculum.

The Rising Tide Foundation for Clinical Cancer Research awarded a three-year, $753,300 grant to Beckman Research Institute of City of Hope to support a clinical trial in acute myeloid leukemia.

UniHealth Foundation awarded a three-year, $733,951 grant to City of Hope to develop an innovative model program focused on improving the care provided to geriatric cancer patients.

A gift of more than $720,000 from the Arnold and Mabel Beckman Foundation will provide support for research efforts at Beckman Research Institute of City of Hope.

Henry L. Guenther Foundation awarded a three-year, $600,000 grant to City of Hope toward the acquisition of a scanning electron microscope to advance research into more effective therapies for disease.

The Gateway for Cancer Research awarded a two-year, $599,450 grant to Beckman Research Institute of City of Hope to support a phase I clinical study for the treatment of malignant glioma.
2015 Spirit of Life® Honorees

The Spirit of Life Award is City of Hope’s highest philanthropic honor. It is given to individuals to celebrate their philanthropy and impact on our mission and our patients. The award is presented to industry, chapter or community leaders and recognizes a lifetime of personal and professional achievement in advancing City of Hope’s lifesaving work. These individuals share a deep commitment to advancing scientific research that will improve treatment for patients everywhere.

Victor Coleman, Hudson Pacific Properties Inc.
Los Angeles Real Estate & Construction Industries Council

Kurt L. Darrow, La Z Boy Inc.
International Home Furnishings Industry

Steve Goddard, PRAVANA
National Professional Salon Industry

Joe Buescher, Food4Less Food Co.
Southern California Food Industries Circle

Daniel H. Grace, Teamsters Local 830
Tri-State Labor & Management Council

Sir Lucian Grainge, Universal Music Group
Music, Film and Entertainment Industry

Christopher G. Kennedy, Joseph P. Kennedy Enterprises
Chicago Construction and Real Estate Council

Jeffrey Kolansky, Esq., Archer & Greiner
Tri-State Labor & Management Council

Joan Lunden, Former Co-anchor, Good Morning America
East End Chapter/Jeanne Kaye League

Ellen Marmur, M.D., Marmur Medical
East End Chapter/Jeanne Kaye League

Michael Miller, Scottsdale Insurance
National Insurance Industry Council

Steve Sakamoto, Hewlett-Packard
National Business Products Industry

Clearence H. Smith, Havertys Furniture
International Home Furnishings Industry

Joe McFarland, The Home Depot
Hardware/Homebuilding Industry

Dan Young, Irvine Company
Construction Industries Alliance

Ron Zeff, Carmel Partners
Northern California Real Estate & Construction Council

Sam Smith performs at the Music, Film and Entertainment Industry’s Spirit of Life Award Dinner honoring Sir Lucian Grainge, CBE of Universal Music Group
City of Hope  
Board of Directors  
Norman C. Payson, M.D.  
Chair of the Board  
Randolph P. Beatty, Ph.D.  
Sheri J. Biler  
Alexander L. Cappello  
Rodney C. Freeman  
Eddy W. Hartenstein  
Selwyn Isakow, Vice Chair  
Michael E. Keane  
Harry Levitt  
Jody Horowitz Marsh  
Anthony E. Scott  

Chairs Emeritus  
Philip L. Engel  
Meyer E. Hersch  
Terry R. Peets  
Gil N. Schwartzberg  
Jack R. Suzar  
Richard S. Ziman  

National Medical Center  
Board of Directors  
Randolph P. Beatty, Ph.D.  
Chair of the Board  
Vincent Chung, M.D.  
Donald Hoffman  
Jacqueline B. Kosecoff, Ph.D.  
Jody Horowitz Marsh  
Richard B. Meyers  
Leslie Popplewell, M.D.  
Claire L. Rothman  
Iris Rothstein  
Ernie C. So  
George Somlo, M.D.  
Mark Wakabayashi, M.D., M.P.H.  

Emeritus and  
Honorary Directors  
Israel J. Freeman  
Robbin L. Itkin  
Michael B. Kaplan  
Stephen B. Kass  
Sidney Kline  
Jacqueline B. Kosecoff, Ph.D.  
Mark Levey  
Claire L. Rothman  
Joseph P. Sanford  
Stephan E. Tow  
Ernie C. So  

Beckman Research Institute  
Board of Directors  
Jody Horowitz Marsh,  
Chair of the Board  
Behnam Badie, M.D.  
Gary E. Freedman  
Art Nemiroff  
Linda Malkas, Ph.D.  
John J. Rossi, Ph.D.  
Iris Rothstein  
Ernie C. So  

City of Hope  
Medical Foundation  
Board of Directors  
Norman C. Payson, M.D.  
Chair of the Board  
James Andersen, M.D.  
William Boswell, M.D.  
Michael A. Friedman, M.D.  
Alexandra Levine, M.D., M.A.C.P.  
Harlan Levine, M.D.  
Robert W. Stone  
Jeffrey Wong, M.D.
Luminaries of the music, film and entertainment industries gather at the 2015 *Spirit of Life* Gala to honor Sir Lucian Grainge CBE, chairman and CEO of Universal Music Group.

The award is City of Hope’s highest honor, and each year recognizes an individual whose work has fundamentally impacted his or her field.
## Selected Financials

City of Hope and Affiliates Consolidated Statements of Financial Position — September 30, 2015 and 2014

*Amounts in thousands*

### Current assets

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$133,293</td>
<td>$126,607</td>
</tr>
<tr>
<td>Investments</td>
<td>815,532</td>
<td>706,186</td>
</tr>
<tr>
<td>Patient accounts receivable, less allowances</td>
<td>206,151</td>
<td>181,568</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Grants and other receivables</td>
<td>49,084</td>
<td>22,239</td>
</tr>
<tr>
<td>Donor restricted unconditional promises to give, net</td>
<td>18,660</td>
<td>18,199</td>
</tr>
<tr>
<td>Prepaid and other</td>
<td>23,512</td>
<td>18,226</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td><strong>1,246,232</strong></td>
<td><strong>1,073,025</strong></td>
</tr>
</tbody>
</table>

### Property, Plant and Equipment

Net of accumulated depreciation of $583,417 in 2014 and $642,949 in 2015

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>679,305</td>
<td>704,109</td>
</tr>
</tbody>
</table>

### Other Assets

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments</td>
<td>371,440</td>
<td>379,648</td>
</tr>
<tr>
<td>Board designated investments</td>
<td>653,354</td>
<td>662,774</td>
</tr>
<tr>
<td>Bond trust funds</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Donor restricted assets</td>
<td>391,695</td>
<td>356,329</td>
</tr>
<tr>
<td>Other assets</td>
<td>46,226</td>
<td>68,161</td>
</tr>
<tr>
<td><strong>Total other assets</strong></td>
<td><strong>1,462,715</strong></td>
<td><strong>1,466,947</strong></td>
</tr>
</tbody>
</table>

### Total Assets

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$3,388,252</td>
<td>$3,244,081</td>
</tr>
</tbody>
</table>

### Current Liabilities

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$161,574</td>
<td>$150,789</td>
</tr>
<tr>
<td>Long-term debt, current portion</td>
<td>72,549</td>
<td>73,726</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td><strong>234,123</strong></td>
<td><strong>224,515</strong></td>
</tr>
</tbody>
</table>

### Long-term Debt, net of current portion

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>630,176</td>
<td>636,925</td>
</tr>
</tbody>
</table>

### Annuity and Split-interest Agreement Obligations

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>16,846</td>
<td></td>
<td>17,574</td>
</tr>
<tr>
<td>Other</td>
<td>57,915</td>
<td>47,795</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>939,060</strong></td>
<td><strong>926,809</strong></td>
</tr>
</tbody>
</table>

### Commitments and Contingencies

### Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>2,054,965</td>
<td>1,960,318</td>
</tr>
<tr>
<td>Restricted</td>
<td>394,227</td>
<td>356,954</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>2,449,192</strong></td>
<td><strong>2,317,272</strong></td>
</tr>
</tbody>
</table>

### Total Liabilities and Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$3,388,252</td>
<td>$3,244,081</td>
</tr>
</tbody>
</table>
### Gross Charges for Patient Services

*Amounts in thousands*

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>%</th>
<th>2014</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare</td>
<td>$1,027,348</td>
<td>33.7%</td>
<td>$843,215</td>
<td>31.8%</td>
</tr>
<tr>
<td>Indemnity insurance</td>
<td>19,676</td>
<td>0.6%</td>
<td>21,024</td>
<td>0.8%</td>
</tr>
<tr>
<td>Managed care contracts</td>
<td>1,569,795</td>
<td>51.5%</td>
<td>1,357,506</td>
<td>51.2%</td>
</tr>
<tr>
<td>Subsidized care</td>
<td>434,247</td>
<td>14.2%</td>
<td>428,553</td>
<td>16.2%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$3,051,066</td>
<td>100.00%</td>
<td>$2,650,298</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

### Patients Treated

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients treated during year</td>
<td>26,913</td>
<td>25,609</td>
</tr>
<tr>
<td>Admissions</td>
<td>6,048</td>
<td>5,876</td>
</tr>
<tr>
<td>Adjusted patient days</td>
<td>129,319</td>
<td>119,208</td>
</tr>
<tr>
<td>Outpatient and infusion visits</td>
<td>301,477</td>
<td>226,855**</td>
</tr>
<tr>
<td>Bone marrow transplants</td>
<td>617</td>
<td>544</td>
</tr>
</tbody>
</table>

**Number updated from the prior year**
### City of Hope and Affiliates Consolidated Statements of Activities for the Years Ended September 30, 2015 and 2014

**Amounts in thousands**

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net patient service revenues</td>
<td>$1,005,065</td>
<td>$798,188</td>
</tr>
<tr>
<td>Contributions and net special event revenues</td>
<td>124,685</td>
<td>112,308</td>
</tr>
<tr>
<td>Royalties and research grants</td>
<td>362,590</td>
<td>322,719</td>
</tr>
<tr>
<td>Other</td>
<td>108,671</td>
<td>136,664</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td><strong>1,601,011</strong></td>
<td><strong>1,369,879</strong></td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td>1,070,613</td>
<td>929,130</td>
</tr>
<tr>
<td>Supporting services</td>
<td>262,042</td>
<td>205,516</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>1,332,655</strong></td>
<td><strong>1,134,646</strong></td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td><strong>268,356</strong></td>
<td><strong>235,233</strong></td>
</tr>
<tr>
<td><strong>Change in net unrealized gain (loss) on investments</strong></td>
<td>$(136,436)</td>
<td>58,272</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>131,920</td>
<td>293,505</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>2,317,272</td>
<td>2,023,767</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>$2,449,192</td>
<td>$2,317,272</td>
</tr>
</tbody>
</table>

### City of Hope and Affiliates Consolidated Statements of Cash Flow for the Years Ended September 30, 2015 and 2014

**Amounts in thousands**

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Changes in net assets</td>
<td>$131,920</td>
<td>$293,505</td>
</tr>
<tr>
<td><strong>Adjustments to reconcile changes in net assets to net cash provided by operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>81,933</td>
<td>68,795</td>
</tr>
<tr>
<td>Net change in operating investments</td>
<td>(35,430)</td>
<td>77,416</td>
</tr>
<tr>
<td>Other changes in operating assets and liabilities</td>
<td>(51,137)</td>
<td>(18,837)</td>
</tr>
<tr>
<td><strong>Total adjustments</strong></td>
<td>(4,634)</td>
<td>127,374</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>127,286</td>
<td>420,879</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from sales of property, plant and equipment</td>
<td>2,322</td>
<td>2,094</td>
</tr>
<tr>
<td>Additions to property, plant and equipment</td>
<td>(55,355)</td>
<td>(103,145)</td>
</tr>
<tr>
<td>Acquisition of other long-term assets</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Change in investments and other</td>
<td>(77,154)</td>
<td>(328,665)</td>
</tr>
<tr>
<td><strong>Net cash investing activities</strong></td>
<td>(130,187)</td>
<td>(429,716)</td>
</tr>
<tr>
<td><strong>Cash flows from financing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net cash provided by financing activities</td>
<td>9,587</td>
<td>6,060</td>
</tr>
<tr>
<td><strong>Net increase (decrease) in cash and cash equivalents</strong></td>
<td>6,686</td>
<td>(2,777)</td>
</tr>
<tr>
<td>Cash and cash equivalents, beginning of year</td>
<td>126,607</td>
<td>129,384</td>
</tr>
<tr>
<td>Cash and cash equivalents, end of year</td>
<td>$133,293</td>
<td>$126,607</td>
</tr>
</tbody>
</table>